title: Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points.
abstract: BACKGROUND
  Coating of stents has been shown to minimize the interactions between platelets, stent surface and vascular response following stent implantation. The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS(®) stent with sirolimus-eluting CYPHER(®) stent for the prevention of symptom-driven clinical end points in a real world clinical setting.
  
  
  METHODS
  This prospective registry with a follow-up period of 24 months was conducted in 90 consecutive patients undergoing coronary artery stenting receiving CYPHER(®) (n = 48) or JANUS(®) (n = 42) stents. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction and target vessel revascularisation, and the secondary end point was clinically driven in-stent restenosis.
  
  
  RESULTS
  The primary combined endpoint occurred in 38% of patients (n = 16) in the JANUS(®) group compared to 10% (n = 5) in the CYPHER(®) group. The relative risk increase of the composite end point was therefore 63% higher in patients receiving JANUS(®) stents compared to the CYPHER(®) stents (crude HR = 1.63, 95% CI = 1.17-2.28, p = 0.004; adjusted HR = 1.79, CI = 1.26-2.55, p = 0.001). Interestingly, 75% of events in the JANUS(®) group occurred during the first 6 months after stent implantation. Similarly, the rate of clinically driven in-stent restenosis was higher in patients receiving JANUS(®) stent (n = 10, 2%) compared to the CYPHER(®) stent (n = 2, 4%). Concordantly, the relative risk for clinically driven in-stent restenosis was 81% higher in the JANUS(®) group compared to the CYPHER(®) group (crude HR = 1.81, 95% CI = 1.08-3.02, p = 0.02; adjusted HR = 2.24, CI = 1.26-3.96, p = 0.006).
  
  
  CONCLUSIONS
  The use of tacrolimus-eluting carbon coated JANUS(®) stent was associated with worse clinical outcome compared to the sirolimus-eluting CYPHER(®) stent in clinical routine use.
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Austria. jolanta.siller-matula@meduniwien.ac.at
authors.forename: J M
authors.initials: JM
authors.lastname: Siller-Matula
authors.forename: I
authors.initials: I
authors.lastname: Tentzeris
authors.forename: B
authors.initials: B
authors.lastname: Vogel
authors.forename: S
authors.initials: S
authors.lastname: Schacherl
authors.forename: R
authors.initials: R
authors.lastname: Jarai
authors.forename: A
authors.initials: A
authors.lastname: Geppert
authors.forename: G
authors.initials: G
authors.lastname: Unger
authors.forename: K
authors.initials: K
authors.lastname: Huber
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002244:Carbon; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003327:Coronary Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D002244:Carbon; D020123:Sirolimus; D016559:Tacrolimus
references.citation: J Am Coll Cardiol. 2007 Feb 13;49(6):734-9
references.pmid: 17291948
references.citation: Catheter Cardiovasc Interv. 2001 Dec;54(4):420-6
references.pmid: 11747173
references.citation: Catheter Cardiovasc Interv. 2009 Feb 1;73(2):243-8
references.pmid: 19156896
references.citation: Clin Res Cardiol. 2009 May;98(5):325-30
references.pmid: 19280084
references.citation: Clin Res Cardiol. 2009 Feb;98(2):89-93
references.pmid: 18853086
references.citation: J Invasive Cardiol. 2003 Oct;15(10):562-5
references.pmid: 14519887
references.citation: EuroIntervention. 2006 May;2(1):45-52
references.pmid: 19755236
references.citation: J Am Coll Cardiol. 2005 Apr 5;45(7):1135-41
references.pmid: 15808774
references.citation: Am J Cardiol. 2007 Apr 15;99(8):1062-6
references.pmid: 17437728
references.citation: Clin Res Cardiol. 2010 Feb;99(2):99-106
references.pmid: 19882098
references.citation: Chin Med J (Engl). 2007 Apr 5;120(7):552-6
references.pmid: 17442201
references.citation: Am J Cardiol. 2000 Apr 1;85(7):821-5
references.pmid: 10758920
references.citation: Thromb Res. 2000 Sep 15;99(6):577-85
references.pmid: 10974344
references.citation: Biomaterials. 2002 Feb;23(3):767-73
references.pmid: 11771697
references.citation: Z Kardiol. 2005 Jul;94(7):445-52
references.pmid: 15997345
references.citation: Am Heart J. 2004 May;147(5):764-73
references.pmid: 15131529
references.citation: Herz. 2002 Sep;27(6):518-26
references.pmid: 12378397
references.citation: Rev Esp Cardiol. 2007 Feb;60(2):197-200
references.pmid: 17338885
references.citation: J Cardiovasc Med (Hagerstown). 2008 Jun;9(6):589-94
references.pmid: 18475127
references.citation: Clin Res Cardiol. 2008 Feb;97(2):118-23
references.pmid: 18087665
references.citation: Catheter Cardiovasc Interv. 2002 Feb;55(2):150-6
references.pmid: 11835638
references.citation: Heart. 2005 Jun;91 Suppl 3:iii20-3
references.pmid: 15919648
references.citation: Am J Cardiol. 2004 Feb 15;93(4):474-7
references.pmid: 14969628
references.citation: Clin Res Cardiol. 2008 Jul;97(7):432-40
references.pmid: 18317669
references.citation: J Interv Cardiol. 2003 Dec;16(6):499-505
references.pmid: 14632947
references.citation: J Invasive Cardiol. 2000 Aug;12(8):389-94
references.pmid: 10953100